MDMA (Ecstasy) Abuse Research Report

  1. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1993;8(2):171-176. doi:10.1038/npp.1993.19.
  2. Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001;3(4):265-279.
  3. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics. 1997;100(4):705-708.
  4. SAMHSA. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville (MD): SAMHSA; 2017.
  5. Passie T, Benzenhöfer U. The History of MDMA as an Underground Drug in the United States, 1960–1979. J Psychoactive Drugs. 2016;48(2):67-75. doi:10.1080/02791072.2015.1128580.
  6. Kiyatkin EA, Kim AH, Wakabayashi KT, Baumann MH, Shaham Y. Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. J Neurosci Off J Soc Neurosci. 2014;34(23):7754-7762. doi:10.1523/JNEUROSCI.0506-14.2014.
  7. Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther. 2011;90(2):246-255. doi:10.1038/clpt.2011.78.
  8. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002;162(4):396-405. doi:10.1007/s00213-002-1131-1.
  9. Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol CJASN. 2008;3(6):1852-1860. doi:10.2215/CJN.02080508.
  10. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 1987;241(1):338-345.
  11. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci Off J Soc Neurosci. 1999;19(12):5096-5107.
  12. O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci Off J Soc Neurosci. 1988;8(8):2788-2803.
  13. Biezonski DK, Meyer JS. The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis. Curr Neuropharmacol. 2011;9(1):84-90. doi:10.2174/157015911795017146.
  14. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry. 2000;68(6):719-725.
  15. Gold LH, Koob GF, Geyer MA. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther. 1988;247(2):547-555.
  16. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1988;1(4):273-277.
  17. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of “Ecstacy” users and their experiences with the drug. Br J Addict. 1992;87(8):1161-1172.
  18. EMCDDA. MDMA (“Ecstasy”) drug profile. January 2015.
  19. DEA. Drugs of Abuse. 2015 Edition: A DEA Resource Guide. 2015.
  20. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med. 1999;16(3):194-197.
  21. Baggott M, Heifets B, Jones R, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. J Am Med Assoc. 2000;284(17):2190.
  22. Tanner-Smith EE. Pharmacological content of tablets sold as “ecstasy”: results from an online testing service. Drug Alcohol Depend. 2006;83(3):247-254. doi:10.1016/j.drugalcdep.2005.11.016.
  23. DEA. Microgram Bulletin. December 2008. Accessed September 19, 2016.
  24. Community Epidemiology Work Group. Proceedings of the Community Epidemiology Work Group. NIDA; 2014.
  25. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168(2):458-470. doi:10.1111/j.1476-5381.2012.02145.x.
  26. NDEWS. NDEWS News.; 2015.
  27. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2000;22(5):513-521. doi:10.1016/S0893-133X(99)00148-7.
  28. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1998;19(4):241-251. doi:10.1016/S0893-133X(98)00013-X.
  29. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav. 2004;29(4):743-752. doi:10.1016/j.addbeh.2004.02.022.
  30. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 1999;55(1-2):105-115.
  31. DEA. Drug Fact Sheet: Ecstasy or MDMA. Accessed February 25, 2016.
  32. Parrott AC. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol Oxf Engl. 2005;19(1):71-83. doi:10.1177/0269881105048900.
  33. Bernschneider-Reif S, Oxler F, Freudenmann RW. The origin of MDMA (“ecstasy”)--separating the facts from the myth. Pharm. 2006;61(11):966-972.
  34. Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addict Abingdon Engl. 2006;101(9):1241-1245. doi:10.1111/j.1360-0443.2006.01511.x.
  35. Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? Am J Psychother. 1986;40(3):393-404.
  36. Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol. 2001;16(8):557-577. doi:10.1002/hup.351.
  37. DEA. Schedules of Controlled Substances; Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substances Act; Remand. 1988;53(34):5156.
  38. DEA. Orangebook. Lists of: Scheduling Actions Controlled Substances Regulated Chemicals. November 2015.
  39. White CM. 3,4-Methylenedioxymethamphetamine’s (MDMA’s) Impact on Posttraumatic Stress Disorder. Ann Pharmacother. 2014;48(7):908-915. doi:10.1177/1060028014532236.
  40. Parrott AC. The potential dangers of using MDMA for psychotherapy. J Psychoactive Drugs. 2014;46(1):37-43. doi:10.1080/02791072.2014.873690.
  41. Grob C. MDMA research: preliminary investigations with human subjects. Int J Drug Policy. 1998;9(2):119-124.
  42. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res. 1996;73(1-2):103-107.
  43. SAMHSA. National Survey on Drug Use and Health, 2002-2014. Rockville, MD: SAMHSA; 2015.
  44. SAMHSA. Results from the 2004 National Survey on Drug Use and Health: National Findings. Rockville, MD: SAMHSA; 2005.
  45. Johnston L, O’Malley P, Miech R, Bachman J, Schulenberg J. Monitoring the Future National Survey Results on Drug Use, 1975-2016: Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, The University of Michigan; 2017.
  46. Palamar JJ, Kamboukos D. An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States. Subst Use Misuse. 2014;49(13):1774-1783. doi:10.3109/10826084.2014.926933.
  47. SAMHSA. Drug Abuse Warning Network, 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: SAMHSA; 2013.
  48. SAMHSA. Treatment Episode Data Set (TEDS): 2004-2014. National Admissions to Substance Abuse Treatment Services. Rockville, MD; 2016.
  49. Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse, Volume 1: Highlights and Executive Summary. NIDA; 1999.
  50. SAMHSA. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. SAMHSA; 2015.
  51. SAMHSA. Risk and Protective Factors and Initiation of Substance Use: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: SAMHSA; 2015.
  52. Chow C, Vallance K, Stockwell T, et al. Sexual identity and drug use harm among high-risk, active substance users. Cult Health Sex. 2013;15(3):311-326. doi:10.1080/13691058.2012.754054.
  53. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX, Hell D. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2000;23(4):388-395. doi:10.1016/S0893-133X(00)00130-5.
  54. Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9(11):1645-1652. doi:10.1093/scan/nst161.
  55. Baggott MJ, Coyle JR, Siegrist JD, Garrison KJ, Galloway GP, Mendelson JE. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol Oxf Engl. February 2016. doi:10.1177/0269881115626348.
  56. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154(2):161-168.
  57. Davison D, Parrott AC. Ecstasy (MDMA) in Recreational Users: Self-Reported Psychological and Physiological Effects. Hum Psychopharmacol Clin Exp. 1997;12:221-226.
  58. Le Roux G, Bruneau C, Lelièvre B, et al. Recreational phenethylamine poisonings reported to a French poison control center. Drug Alcohol Depend. 2015;154:46-53. doi:10.1016/j.drugalcdep.2015.05.048.
  59. Armenian P, Mamantov TM, Tsutaoka BT, et al. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series. J Intensive Care Med. 2013;28(4):252-258. doi:10.1177/0885066612445982.
  60. Dafters RI, Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) but not by fenfluramine. Psychopharmacology (Berl). 1998;138(2):207-212.
  61. Ridpath A, Driver CR, Nolan ML, et al. Illnesses and deaths among persons attending an electronic dance-music festival - New York City, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(50):1195-1198.
  62. Moritz ML, Kalantar-Zadeh K, Ayus JC. Ecstacy-associated hyponatremia: why are women at risk? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(9):2206-2209. doi:10.1093/ndt/gft192.
  63. Baggott MJ, Garrison KJ, Coyle JR, et al. MDMA Impairs Response to Water Intake in Healthy Volunteers. Adv Pharmacol Sci. 2016;2016:2175896. doi:10.1155/2016/2175896.
  64. van Dijken GD, Blom RE, Hené RJ, Boer WH, NIGRAM Consortium  null. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(9):2277-2283. doi:10.1093/ndt/gft023.
  65. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000;133(12):969-973.
  66. Cohen RS. Subjective reports on the effects of the MDMA (’ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(7):1137-1145.
  67. Lamers CTJ, Ramaekers JG, Muntjewerff ND, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol Oxf Engl. 2003;17(4):379-387.
  68. Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos Biol Fate Chem. 2014;42(1):119-125. doi:10.1124/dmd.113.053678.
  69. da Silva DD, Silva E, Carvalho F, Carmo H. Mixtures of 3,4-methylenedioxymethamphetamine (ecstasy) and its major human metabolites act additively to induce significant toxicity to liver cells when combined at low, non-cytotoxic concentrations. J Appl Toxicol JAT. 2014;34(6):618-627. doi:10.1002/jat.2885.
  70. Camarasa J, Pubill D, Escubedo E. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res. 2006;1111(1):72-82. doi:10.1016/j.brainres.2006.06.087.
  71. Dias da Silva D, Carmo H, Silva E. The risky cocktail: what combination effects can we expect between ecstasy and other amphetamines? Arch Toxicol. 2013;87(1):111-122. doi:10.1007/s00204-012-0929-9.
  72. Angoa-Pérez M, Kane M, Briggs D, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem. 2013;125(1):102-110.
  73. Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther. 2009;86(2):160-166. doi:10.1038/clpt.2009.62.
  74. Navarro-Zaragoza J, Ros-Simó C, Milanés M-V, Valverde O, Laorden M-L. Binge Ethanol and MDMA Combination Exacerbates Toxic Cardiac Effects by Inducing Cellular Stress. PloS One. 2015;10(10):e0141502. doi:10.1371/journal.pone.0141502.
  75. Ros-Simó C, Ruiz-Medina J, Valverde O. Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice. Psychopharmacology (Berl). 2012;221(3):511-525. doi:10.1007/s00213-011-2598-4.
  76. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J Pharmacol Exp Ther. 2002;302(3):898-907.
  77. Curran HV, Travill RA. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): week-end “high” followed by mid-week low. Addict Abingdon Engl. 1997;92(7):821-831.
  78. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl). 1998;139(3):261-268.
  79. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of “ecstasy” (MDMA) consumption in 430 regular users. Hum Psychopharmacol. 2003;18(7):507-517. doi:10.1002/hup.529.
  80. Verheyden SL, Hadfield J, Calin T, Curran HV. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: evidence of gender differences. Psychopharmacology (Berl). 2002;161(1):23-31. doi:10.1007/s00213-001-0995-9.
  81. Droogmans S, Cosyns B, D’haenen H, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol. 2007;100(9):1442-1445. doi:10.1016/j.amjcard.2007.06.045.
  82. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003;63(6):1223-1229. doi:10.1124/mol.63.6.1223.
  83. Morgan MJ. Memory deficits associated with recreational use of “ecstasy” (MDMA). Psychopharmacology (Berl). 1999;141(1):30-36.
  84. Wagner D, Tkotz S, Koester P, Becker B, Gouzoulis-Mayfrank E, Daumann J. Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study. Front Neurosci. 2015;9:445. doi:10.3389/fnins.2015.00445.
  85. May AL, Parrott AC. Greater sexual risk-taking in female and male recreational MDMA/ecstasy users compared with alcohol drinkers: a questionnaire study. Hum Psychopharmacol. 2015;30(4):272-275. doi:10.1002/hup.2432.
  86. Novoa RA, Ompad DC, Wu Y, Vlahov D, Galea S. Ecstasy use and its association with sexual behaviors among drug users in New York City. J Community Health. 2005;30(5):331-343.
  87. Theall KP, Elifson KW, Sterk CE. Sex, touch, and HIV risk among ecstasy users. AIDS Behav. 2006;10(2):169-178. doi:10.1007/s10461-005-9059-1.
  88. Degenhardt L. Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference? Cult Health Sex. 2005;7(6):599-614. doi:10.1080/13691050500349875.
  89. Gough B, Ali SF, Slikker W, Holson RR. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav. 1991;39(3):619-623.
  90. Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol. 1987;36(5):747-755.
  91. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synap N Y N. 2001;39(1):32-41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3.
  92. Sabol KE, Seiden LS. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res. 1998;806(1):69-78.
  93. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol. 1992;215(2-3):153-160.
  94. Verrico CD, Lynch L, Fahey MA, Fryer A-K, Miller GM, Madras BK. MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol Oxf Engl. 2008;22(2):187-202. doi:10.1177/0269881107083639.
  95. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA (“Ecstasy”) users. Neurology. 1998;51(6):1532-1537.
  96. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology. 2000;55(2):294-296.
  97. Cuyas E, Robledo P, Pizarro N, et al. 3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. Neurotox Res. 2014;25(2):161-169. doi:10.1007/s12640-013-9416-1.
  98. Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016;8(1). doi:10.3390/nu8010056.
  99. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA (’ecstasy’) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend. 1998;52(1):85-90.
  100. Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy “ecstasy” (MDMA) polydrug users. Drug Alcohol Depend. 2000;60(1):105-110.
  101. Verkes RJ, Gijsman HJ, Pieters MS, et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl). 2001;153(2):196-202.
  102. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA (’ecstasy’). Br J Psychol Lond Engl 1953. 2000;91 ( Pt 2):181-188.
  103. Bosch OG, Wagner M, Jessen F, et al. Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PloS One. 2013;8(4):e61234. doi:10.1371/journal.pone.0061234.
  104. Obrocki J, Buchert R, Väterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasylong-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry J Ment Sci. 1999;175:186-188.
  105. Mueller F, Lenz C, Steiner M, et al. Neuroimaging in moderate MDMA use: A systematic review. Neurosci Biobehav Rev. 2015;62:21-34. doi:10.1016/j.neubiorev.2015.12.010.
  106. Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav. 2002;71(4):845-855.
  107. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend. 2002;68(2):195-207.
  108. Singer LT, Moore DG, Min MO, et al. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK. Hum Psychopharmacol. 2015;30(4):290-294. doi:10.1002/hup.2459.
  109. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci Off J Soc Neurosci. 2001;21(9):3228-3235.
  110. Williams MT, Skelton MR, Longacre ID, et al. Neuronal reorganization in adult rats neonatally exposed to (±)-3,4-methylenedioxymethamphetamine. Toxicol Rep. 2014;1:699-706. doi:10.1016/j.toxrep.2014.08.018.
  111. Colado MI, O’Shea E, Granados R, Misra A, Murray TK, Green AR. A study of the neurotoxic effect of MDMA (’ecstasy’) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol. 1997;121(4):827-833. doi:10.1038/sj.bjp.0701201.
  112. Koprich JB, Chen E-Y, Kanaan NM, Campbell NG, Kordower JH, Lipton JW. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol. 2003;25(5):509-517.
  113. Canales JJ, Ferrer-Donato A. Prenatal exposure to alcohol and 3,4-methylenedioxymethamphetamine (ecstasy) alters adult hippocampal neurogenesis and causes enduring memory deficits. Dev Neurosci. 2014;36(1):10-17. doi:10.1159/000356820.
  114. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1-10. doi:10.1016/j.drugalcdep.2009.09.009.
  115. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC. MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci. 2007;26(11):3229-3236. doi:10.1111/j.1460-9568.2007.05932.x.
  116. Schenk S, Aronsen D. Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA (’Ecstasy’) Substance Use Disorder. Curr Top Behav Neurosci. December 2015. doi:10.1007/7854_2015_421.
  117. Cottler LB, Leung KS, Abdallah AB. Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study. Addict Abingdon Engl. 2009;104(10):1679-1690. doi:10.1111/j.1360-0443.2009.02649.x.
  118. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol. 2001;16(8):599-606. doi:10.1002/hup.343.
  119. Davis AK, Rosenberg H. The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. J Psychoactive Drugs. 2014;46(2):154-161. doi:10.1080/02791072.2014.901586.
  120. Falck RS, Carlson RG, Wang J, Siegal HA. Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users. Drug Alcohol Depend. 2004;74(1):45-54. doi:10.1016/j.drugalcdep.2003.11.009.
  121. Champion KE, Newton NC, Stapinski LA, Teesson M. Effectiveness of a universal Internet-based prevention program for ecstasy and new psychoactive substances: a cluster randomised controlled trial. Addict Abingdon Engl. February 2016. doi:10.1111/add.13345.
  122. Ciudad-Roberts A, Camarasa J, Pubill D, Escubedo E. Heteromeric nicotinic receptors are involved in the sensitization and addictive properties of MDMA in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:201-209. doi:10.1016/j.pnpbp.2013.02.013.
  123. Rodríguez-Arias M, Valverde O, Daza-Losada M, Blanco-Gandía MC, Aguilar MA, Miñarro J. Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: role of CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:77-84. doi:10.1016/j.pnpbp.2013.07.013.
  124. Roger-Sánchez C, Rodríguez-Arias M, Miñarro J, Aguilar MA. Involvement of 5-hydroxytryptamine 5-HT₃ serotonergic receptors in the acquisition and reinstatement of the conditioned place preference induced by MDMA. Eur J Pharmacol. 2013;714(1-3):132-141. doi:10.1016/j.ejphar.2013.06.005.
  125. Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PloS One. 2012;7(5):e36476. doi:10.1371/journal.pone.0036476.
  126. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME. α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol. 2013;33(5):658-666. doi:10.1097/JCP.0b013e3182979d32.